During the corresponding time, Xilio Therapeutics Inc recorded a revenue increase by 131.22 % year on year, sequentially revenue grew by 47.79 %. While revenue at the Xilio Therapeutics Inc 's corporate clients
Xilio Therapeutics Inc's Comment on Sales, Marketing and Customers
Customers are subject to various federal and state healthcare laws and regulations affecting business and financial arrangements. These include the U.S. federal Anti-Kickback Statute; federal civil and criminal false claims laws such as the False Claims Act; federal civil monetary penalty and false statement laws related to pricing for government programs; the Health Insurance Portability and Accountability Act (HIPAA) and its amendments, including the Health Information Technology for Economic and Clinical Health Act and the Final Omnibus Rule; the federal false statements statute; the Foreign Corrupt Practices Act; and the federal Physician Payments Sunshine Act under the Patient Protection and Affordable Care Act (PPACA), as amended by the Health Care Education Reconciliation Act. These laws regulate activities including remuneration for referrals, submission of false claims to the federal government, pricing information disclosures, safeguarding health information privacy and security, prohibiting improper payments to non-U.S. officials, and reporting payments to physicians and other healthcare providers to the Centers for Medicare & Medicaid Services within the Department of Health and Human Services.
Xilio Therapeutics Announces Promising Results and Plans for Phase 2 Trial in Colorectal Cancer Xilio Therapeutics, a leading biotechnology company, recently declared the commencement of patient enrollment for a Phase 1 combination trial of XTX101, its flagship tumor-activated, Fc-enhanced anti-CTLA-4 therapy. Additionally, the company shared updated data from its Phase 1 monotherapy study. These developments are expected to pave the way for a planned Phase 2 trial targeting microsatellite stable colorectal cancer (MSS CRC). The Phase 1 combination trial aims to evaluate the safety and efficacy of XTX101, which selectively targets tumor cells while preserving healthy tissue. By enhancing the anti-CTL...
Xilio Therapeutics Inc’s Comment on Sales, Marketing and Customers
Customers are subject to various federal and state healthcare laws and regulations affecting business and financial arrangements. These include the U.S. federal Anti-Kickback Statute; federal civil and criminal false claims laws such as the False Claims Act; federal civil monetary penalty and false statement laws related to pricing for government programs; the Health Insurance Portability and Accountability Act (HIPAA) and its amendments, including the Health Information Technology for Economic and Clinical Health Act and the Final Omnibus Rule; the federal false statements statute; the Foreign Corrupt Practices Act; and the federal Physician Payments Sunshine Act under the Patient Protection and Affordable Care Act (PPACA), as amended by the Health Care Education Reconciliation Act. These laws regulate activities including remuneration for referrals, submission of false claims to the federal government, pricing information disclosures, safeguarding health information privacy and security, prohibiting improper payments to non-U.S. officials, and reporting payments to physicians and other healthcare providers to the Centers for Medicare & Medicaid Services within the Department of Health and Human Services.
Sources:
Xilio Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Xilio Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Xilio Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
